Key features and details
- Mouse monoclonal [UCHL1] to CD45RO (PE)
- Suitable for: IP, IHC-P, IHC-Fr, Flow Cyt
- Reacts with: Human
- Conjugation: PE. Ex: 488nm, Em: 575nm
- Isotype: IgG2a
Product nameAnti-CD45RO antibody [UCHL1] (PE)
See all CD45RO primary antibodies
DescriptionMouse monoclonal [UCHL1] to CD45RO (PE)
ConjugationPE. Ex: 488nm, Em: 575nm
SpecificityRecognizes CD45R0, a 180 kDa low molecular weight isoform of the leukocyte common antigen (LCA). The antigen is expressed on a subset of memory/activated T cells and on cortical thymocytes.
Tested applicationsSuitable for: IP, IHC-P, IHC-Fr, Flow Cytmore details
Species reactivityReacts with: Human
Human IL-2 dependent T cells
- Flow Cyt: Human peripheral blood lymphocytes.
The conjugate is purified by size exclusion chromatography and adjusted for direct use in flow cytometry.
Storage instructionsShipped at 4°C. Store at +4°C. Do Not Freeze. Store In the Dark.
Storage bufferPreservative: 0.09% Sodium azide
Constituents: 0.1% Gelatin, 0.88% Sodium chloride, 0.12% Monobasic dihydrogen sodium phosphate
Concentration information loading...
Our Abpromise guarantee covers the use of ab77217 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IP||Use at an assay dependent concentration.|
|IHC-P||Use at an assay dependent concentration.|
|IHC-Fr||Use at an assay dependent concentration.|
|Flow Cyt||Use 5µl for 105-8 cells.
Use 5µl in a final volume of 100µl.
ab91363 - Mouse monoclonal IgG2a, is suitable for use as an isotype control with this antibody.
FunctionProtein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. Dephosphorylates LYN, and thereby modulates LYN activity.
Involvement in diseaseDefects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain.
Sequence similaritiesBelongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
Contains 2 fibronectin type-III domains.
Contains 2 tyrosine-protein phosphatase domains.
DomainThe first PTPase domain interacts with SKAP1.
modificationsHeavily N- and O-glycosylated.
Cellular localizationMembrane. Membrane raft. Colocalized with DPP4 in membrane rafts.
- Information by UniProt
- B220 antibody
- CD45 antibody
- cd45 antigen antibody
ab77217 has not yet been referenced specifically in any publications.